Escalation Study of BTP-114 in Patients With Advanced Solid Tumors and BRCA or DNA Repair Mutation

Trial Profile

Escalation Study of BTP-114 in Patients With Advanced Solid Tumors and BRCA or DNA Repair Mutation

Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Jun 2017

At a glance

  • Drugs BTP 114 (Primary)
  • Indications Breast cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Placon Therapeutics
  • Most Recent Events

    • 28 Oct 2016 Status changed from planning to recruiting.
    • 30 Mar 2016 New trial record
    • 23 Mar 2016 According to a Placon Therapeutics media release, the US FDA has accepted an Investigational New Drug (IND) application of BTP-114 to begin clinical evaluation in cancer patients.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top